These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34640606)

  • 1. Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment.
    Hadjiaggelidou C; Katodritou E
    J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced frequency and functional defects of CD4
    Luo L; Zeng X; Huang Z; Luo S; Qin L; Li S
    Reprod Biol Endocrinol; 2020 Jun; 18(1):62. PubMed ID: 32522204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
    Kochin V; Nishikawa H
    Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.
    Jiang Z; Zhu H; Wang P; Que W; Zhong L; Li XK; Du F
    MedComm (2020); 2022 Jun; 3(2):e137. PubMed ID: 35474948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of regulatory T cells in multiple myeloma progression].
    Kawano Y
    Rinsho Ketsueki; 2021; 62(4):299-304. PubMed ID: 33967155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
    Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
    [No Abstract]   [Full Text] [Related]  

  • 9. CD4+CD25+ regulatory T cells in tumor immunity.
    Chen X; Du Y; Lin X; Qian Y; Zhou T; Huang Z
    Int Immunopharmacol; 2016 May; 34():244-249. PubMed ID: 26994448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation.
    Ke X; Zhang S; Xu J; Liu G; Zhang L; Xie E; Gao L; Li D; Sun R; Wang F; Pan S
    Cancer Immunol Immunother; 2016 May; 65(5):587-99. PubMed ID: 27000869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression.
    Dahlhoff J; Manz H; Steinfatt T; Delgado-Tascon J; Seebacher E; Schneider T; Wilnit A; Mokhtari Z; Tabares P; Böckle D; Rasche L; Martin Kortüm K; Lutz MB; Einsele H; Brandl A; Beilhack A
    Leukemia; 2022 Mar; 36(3):790-800. PubMed ID: 34584204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
    Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
    Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.
    Zhuo C; Xu Y; Ying M; Li Q; Huang L; Li D; Cai S; Li B
    Immunol Res; 2015 Mar; 61(3):338-47. PubMed ID: 25608795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.
    Braga WM; da Silva BR; de Carvalho AC; Maekawa YH; Bortoluzzo AB; Rizzatti EG; Atanackovic D; Colleoni GW
    Cancer Immunol Immunother; 2014 Nov; 63(11):1189-97. PubMed ID: 25099367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
    Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
    PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.
    Pan XD; Mao YQ; Zhu LJ; Li J; Xie Y; Wang L; Zhang GB
    Chin Med J (Engl); 2012 Jun; 125(11):2004-11. PubMed ID: 22884069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice.
    Li X; Meng Y; Plotnikoff NP; Youkilis G; Griffin N; Wang E; Lu C; Shan F
    Cancer Biol Ther; 2015; 16(3):450-9. PubMed ID: 25701137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape.
    Sarkar T; Dhar S; Sa G
    Curr Res Immunol; 2021; 2():132-141. PubMed ID: 35492399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-β1.
    Yuan XL; Chen L; Zhang TT; Ma YH; Zhou YL; Zhao Y; Wang WW; Dong P; Yu L; Zhang YY; Shen LS
    World J Gastroenterol; 2011 Apr; 17(15):2019-27. PubMed ID: 21528082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.